Organovo's fatty liver disease drug meets main goal in mid-stage study (updated)

VivoSim Labs

15/04/2024 13:23

(Adds shares in paragraph 1, details throughout)
       April 15 (Reuters) - Organovo Holdings  ONVO.O  said on
Monday its experimental drug to treat a type of fatty liver
disease met the main goal in a mid-stage study, sending its
shares up nearly 27% in premarket trade.
        The non-steroidal drug, FXR314, helped significantly
reduce liver fat in patients with metabolic function-associated
steatohepatitis (MASH), previously known as non-alcoholic
steatohepatitis.
  
        FXR314 was also found to be safe and well-tolerated,
Organovo said.   
  
        The company expects to present detailed findings of the
study at an upcoming conference.   
  
              
  
    

 (Reporting by Mariam Sunny in Bengaluru; Editing by Devika
Syamnath)
 ((Mariam.ESunny@thomsonreuters.com;))